Symphogen also announced today that new pre-clinical data will be presented at the Annual Meeting of the American Association for Cancer Research in New Orleans. At the poster session on Growth Factor Receptors and Surface Antigens as Therapeutic Targets, Monday April 18, 2016 8:00 AM – 12:00 PM the following two posters will be presented:
A novel synergistic antibody pair targeting non-overlapping epitopes of MET effectively inhibits MET-driven cancer models (Abstract # 1218).
Sym015, a novel antibody mixture targeting non-overlapping epitopes of MET, effectively inhibits growth of MET dependent tumors and overcomes resistance to a single monoclonal antibody (Abstract # 1219).
South Texas Accelerated Research Therapeutics (START) directs clinical trials of novel anticancer agents using a high quality and innovative information technology infrastructure to ensure accurate and rapid clinical trials in a setting that emphasizes personalized and compassionate clinical care. START’s head office is located in San Antonio, Texas, in the heart of the South Texas Medical Center.
For additional information, please contact:
Chief Executive Officer
Phone: + 45 22 10 99 59
Chief Scientific and Medical Officer
Phone: + 45 20 55 26 04
Consilium Strategic Communications
Mary-Jane Elliott, Amber Fennell, Lindsey Neville
Phone: +44 20 3709 5700